文献速递临床生化质量管理与危急值

同型半胱氨酸LC-MS/MS方法分析性能评价与室内质控策略设计

Evaluation of analytical performance of homocysteine LC-MS/MS assay and design of internal quality control strategy.
PubMed 文献 · Clin Chem Lab Med · 2023-01-13

该研究以同型半胱氨酸LC-MS/MS实验室自建方法为例,用生物学变异数据库的「理想规格」作为质量目标,基于室间质评样本计算偏倚、连续6个月室内质控计算CV,并用Sigma度量评价分析性能、以Westgard Sigma规则设计个体化室内质控策略。结果显示CV%为2.57-4.01%(p=0.75),绝对偏倚%为1.23和1.87%,Sigma度量4.02和4.30,分析性能为「良好」,建议采用13s/22s/R4s/41s多规则(n=4,r=1)、运行规模200个样本的质控方案,质量目标指数均大于1.2提示需改进正确度。

要点

  • Hcy LC-MS/MS自建方法Sigma度量为4.02和4.30,分析性能达「良好」水平。
  • 建议室内质控采用13s/22s/R4s/41s多规则,n=4、r=1,运行规模200个样本。
  • 质量目标指数均大于1.2,提示应优先改进正确度,校准偏倚是主要影响因素。

核心结论

  • 该Hcy LC-MS/MS实验室自建方法的分析性能符合六西格玛评级水平,达到「良好」(四西格玛)。
  • 临床实践提示校准偏倚是影响正确度的主要因素。

研究设计与样本

  • 以Hcy的LC-MS/MS实验室自建方法为例,采用生物学变异数据库的「理想规格」作为质量目标。
  • 基于室间质评样本计算偏倚,并通过连续6个月室内质控测定计算变异系数。
  • 以计算的Sigma度量评价分析性能,并用Westgard Sigma规则结合运行规模设计室内质控策略。

主要发现

  • 6个月内116天,IQC 1与IQC 2各收集850个数据点。
  • 月变异系数CV%为2.57-4.01%,差异无统计学意义(p值:0.75)。
  • IQC1和IQC2的绝对偏倚%分别为1.23和1.87%。
  • 允许总误差(TEa)选取为15.5%,Sigma度量分别为4.02和4.30,分析性能为「良好」。
  • 质量目标指数(QGI)值均大于1.2,提示正确度需要改进。

关键数值与推荐

  • 允许总误差(TEa)选取为15.5%。
  • Sigma度量为4.02和4.30,分析性能评级为「良好」。
  • 建议Hcy室内质控方案采用13s/22s/R4s/41s多规则(n=4,r=1),运行规模为200个样本。
  • 质量目标指数(QGI)值均大于1.2,提示正确度需改进。

临床怎么用

  • 可按Westgard Sigma规则结合运行规模为该类LC-MS/MS自建方法设计个体化室内质控方案。
  • 当QGI大于1.2时,应优先排查并改进正确度,关注校准偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become a common technique in clinical laboratories in recent years. Because most methods are laboratory-developed tests (LDTs), their reproducibility and quality control (QC) have been controversial. In this study, Westgard Sigma Rules were used to evaluate the analytical performance and establish an individualised internal QC (IQC) strategy for these LDTs. METHODS: Taking the LC-MS/MS LDT method for homocysteine (Hcy) as an example, the 'desirable specifications' from the Biological Variation Database were used as quality goals. Based on the external quality assessment (EQA) samples, bias was calculated and the coefficient of variation (CV) was also calculated by IQC measurements for six consecutive months. The analytical performance was evaluated by calculated sigma metrics and an IQC strategy was designed using the Westgard Sigma Rules with run size. RESULTS: Over 116 days within 6 months, a total of 850 data points were collected for each of IQC 1 and IQC 2. The monthly coefficient of variation CV% was 2.57-4.01%, which was non-significant (p-value: 0.75). The absolute bias% for IQC1 and IQC2 was 1.23 and 1.87%, respectively. The allowable total error (TEa) was selected as 15.5%, Sigma metrics were 4.02 and 4.30, and the analytical performance was 'Good'. The 13s/22s/R4s/41s multi rules (n=4, r=1) with a run size of 200 samples were suggested for the Hcy IQC scheme. The quality goal index (QGI) values were over 1.2, indicating that trueness needed to be improved. CONCLUSIONS: The analytical performance of the Hcy LC-MS/MS LDT conformed to the Six Sigma rating level, achieving 'good' (four Sigma). Clinical practice indicated that calibration bias was the primary factor affecting trueness.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Zhao F, Pan G, Hong M, et al. Evaluation of analytical performance of homocysteine LC-MS/MS assay and design of internal quality control strategy. Clin Chem Lab Med. 2023. PMID: 36635945. doi:10.1515/cclm-2022-0805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。